Retrospective analysis of interventional treatment of hepatic metastasis from gastroenteropancreatic neuroendocrine tumors

被引:0
|
作者
Peng Liu [1 ]
Xu Zhu [1 ]
Jie Li [2 ]
Ming Lu [2 ]
Jiahua Leng [3 ]
Ying Li [4 ]
Jiangyuan Yu [5 ]
机构
[1] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Interventional Therapy,Peking University Cancer Hospital & Institute
[2] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Gastroenterological Oncology,Peking University Cancer Hospital & Institute
[3] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Center of Gastrointestinal Surgery Unit Ⅲ,Peking University Cancer Hospital & Institute
[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital & Institute
[5] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Department of Nuclear Medicine,Peking University Cancer Hospital & Institute
基金
中国国家自然科学基金;
关键词
Gastroenteropancreatic neuroendocrine tumors; hepatic metastasis; angiography; interventional treatment; retrospective analysis;
D O I
暂无
中图分类号
R735 [消化系肿瘤];
学科分类号
100214 ;
摘要
Objective: To analyze the angiography appearance of liver metastases from gastroenteropancreatic neuroendocrine tumors(GEP-NETs),and evaluate the clinical efficacy and prognostic factors of interventional treatment for hepatic metastases.Methods: Fifty GEP-NETs patients with hepatic metastases were treated from January 2012 to December 2016,and received transarterial embolization(TAE) in the hepatic tumor or hepatic arterial infusion chemotherapy(HAIC).All patients received 179 times of the intervention therapy in total.Results: Blood supplies were identified in the 50 cases with angiography,which showed that 35 cases had abundant vessels,while 15 cases had poor blood supply.Twenty-two cases were found either collateral blood supply,or portal vein invasion or arterial-portal vein fistula.The best curative efficacy was complete remission(CR)in 4 cases,partial remission(PR) in 28 cases and stable disease(SD) in 18 cases during the process of treatment.The angiography(P=0.047) and the frequency of intervention(P=0.037) showed significantly statistical difference with Kaplan-Meier analysis.The Cox analysis showed that more than 3 times of interventional therapy was an independent prognostic factor.Conclusions: Interventional treatment is safe and effective for GEP-NETs,and is beneficial to patients with main hepatic metastases after endocrine therapy.
引用
收藏
页码:581 / 586
页数:6
相关论文
共 50 条
  • [21] Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Saif, Muhammad Wasif
    Fu, Julie
    Smith, Melissa H.
    Weinstein, Barbara
    Relias, Valerie
    Daly, Kevin P.
    JOURNAL OF PANCREATIC CANCER, 2018, 4 (01): : 64 - 71
  • [22] A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients gastroenteropancreatic with functional neuroendocrine tumors
    Berkovic, Maja Cigrovski
    Altabas, Velimir
    Herman, Davorka
    Hrabar, Davor
    Goldoni, Vesna
    Vizner, Branka
    Zjacic-Rotkvic, Vanja
    COLLEGIUM ANTROPOLOGICUM, 2007, 31 (02) : 531 - 534
  • [23] Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
    Smith-Palmer, J.
    Leeuwenkamp, O. R.
    Virk, J.
    Reed, N.
    BMC CANCER, 2021, 21 (01)
  • [24] Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland
    J. Smith-Palmer
    O. R. Leeuwenkamp
    J. Virk
    N. Reed
    BMC Cancer, 21
  • [25] Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center
    Cruz-Diaz, Wagner Eduardo
    Paitan, Victor
    Medina, Jersinho
    Flores, Raymundo
    Haro-Varas, Juan
    Mantilla, Raul
    Castro-Oliden, Victor
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (12)
  • [26] Interventional Radiological Treatment of Intercostal Artery Bleedings - a Retrospective Analysis
    Kupczyk, Patrick
    Meyer, Carsten
    Thomas, Daniel
    Schild, Hans Heinz
    Pieper, Claus Christian
    ZENTRALBLATT FUR CHIRURGIE, 2017, 142 (04): : 404 - 410
  • [27] ASO Visual Abstract: A Novel Liver Metastasis Score for Patients Undergoing Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: A Multi-Institutional Study
    Zheng, Qi-Xuan
    Xu, Jia-Hao
    Yang, Fa-Ji
    Liu, Zhi-Peng
    Wang, Ming-Da
    Hao, Yi-Jie
    Li, Chao
    Niu, Zhe-Yu
    Xu, Xin-Fei
    Gao, Heng-Jun
    Li, Yi-Fan
    Gong, Jin-Bo
    Chen, Zhong
    Pawlik, Timothy M.
    Shen, Feng
    Lu, Jun
    Yang, Tian
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (02) : 1195 - 1196
  • [28] Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
    Strom, Torbjorn
    Kozlovacki, Gordana
    Myrenfors, Peter
    Almquist, Martin
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 1799 - 1807
  • [29] Treatment options for peritoneal metastases from hepato-pancreato-biliary tumors and neuroendocrine tumors
    Stroehlein, Michael A.
    Seefeldt, Simone
    Lange, Jonas
    Bulian, Dirk R.
    Heiss, Markus M.
    CHIRURGIE, 2022, 93 (12): : 1139 - 1143
  • [30] Eighteen cases of renal aneurysms: Clinical retrospective analysis and experience of endovascular interventional treatment
    Lu, Tao
    Lin, Bin
    Zhang, Yan-ping
    Zhang, Jian-hui
    Luo, Jie-Wei
    Tang, Yi
    Fang, Zhu-Ting
    FRONTIERS IN SURGERY, 2023, 10